Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 ...

Sees FY26 adjusted EBITDA greater than $300M. “In 2026, we remain focused on our core priorities of maximizing LINZESS, ...

Ironwood expects 2026 Linzess US net sales of $1.125 billion-$1.175 billion, with total revenue expectation of $450 ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

Beyond LINZESS, Ironwood is advancing its pipeline with apraglutide, a next-generation long-acting synthetic GLP-2 analog being developed for short bowel syndrome with intestinal failure (SBS-IF). The ...

On Oct 16, we issued an updated research report on Ironwood Pharmaceuticals, Inc. IRWD. This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of ...

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer ...

– The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – “This latest ANDA settlement with Teva reinforces our belief in the strength of the LINZESS ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...

There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation (CIC) market. And the way some industry watchers see it, it may not be long before the ...